Tipo Sanguíneo
"Pacientes com tipos sanguíneos B e AB que receberam um teste eram mais propensos a testar positivo e o tipo sanguíneo O era menos propenso a testar positivo. Pacientes Rh+ foram mais propensos a testar positivo."
"Patients with blood types B and AB who received a test were more likely to test positive and blood type O was less likely to test positive. Rh+ patients were more likely to test positive."
 | This study aimed to determine if there is an association between ABO blood type and severity of COVID-19 defined by intubation or death as well as ascertain if there is variability in testing positive for COVID-19 between blood types. In a multi-institutional study, all adult patients who tested pos … pubmed.ncbi.nlm.nih.gov |
"Os grupos sanguíneos não-O tornam-se, assim, um alvo preferencial para o vírus, enquanto os indivíduos do grupo sanguíneo O(H), sem as enzimas determinantes do fenótipo A/B e ligando-se ao vírus sozinho pela formação do antígeno híbrido do tipo H, têm menos contato com o vírus e manter as atividades críticas de isoaglutinina anti-A e anti-B, exercidas pela ancestral IgM, que é considerada a ponta de lança humoral da imunidade inata"
"The non-O blood groups thus become a preferred target for the virus, whereas blood group O(H) individuals, lacking the A/B phenotype-determining enzymes and binding the virus alone by hybrid H-type antigen formation, have the least molecular contact with the virus and maintain the critical anti-A and anti-B isoagglutinin activities, exerted by the ancestral IgM, which is considered the humoral spearhead of innate immunity"
1. Introduction. Using a translational study, Preece et al. (2002) revealed how measles viruses undergo specific glycosylation when grown in cells that express blood group A, B, and O(H) antigens. Thus, they probably also demonstrated what occurs in human cells after SARS-CoV-2 infection. In view of the unknown native glycoprotein envelope of SARS-CoV-2, in the current paper I present a ... www.ncbi.nlm.nih.gov |
"Encontramos prevalência de infecção ligeiramente aumentada entre os tipos não-O. O risco de intubação foi diminuído entre os tipos A e aumentado entre os tipos AB e B, em comparação com o tipo O, enquanto o risco de morte foi aumentado para o tipo AB e diminuído para os tipos A e B. Estimamos que o tipo sanguíneo Rh negativo tenha um efeito protetor para todos os três resultados. Nossos resultados se somam ao crescente corpo de evidências sugerindo que o tipo sanguíneo pode desempenhar um papel no COVID-19."
"We find slightly increased infection prevalence among non-O types. Risk of intubation was decreased among A and increased among AB and B types, compared with type O, while risk of death was increased for type AB and decreased for types A and B. We estimate Rh-negative blood type to have a protective effect for all three outcomes. Our results add to the growing body of evidence suggesting blood type may play a role in COVID-19."
| The rapid global spread of the novel coronavirus SARS-CoV-2 has strained healthcare and testing resources, making the identification and prioritization of individuals most at-risk a critical challenge. Recent evidence suggests blood type may affect risk of severe COVID-19. Here, we use observational … pubmed.ncbi.nlm.nih.gov |
Sabendo isto, é discriminatório aplicar as mesmas medidas ditas de saúde, sanitárias, passes, certificados ou outro tipo de medida,
para discriminar pessoas com diferentes tipos de sangue.
Além do mais visto a tecnologia mRNA altera o DNA da pessoa, passa a ser discriminatório distinguir pessoas através de produto inoculado, genética, ou mesmo tipo sanguíneo.
Fonte:
 | Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a recent study showed that SARS-CoV-2 RNA can be reverse-transcribed and integrated into the genome of human cells. In this study, we investigated the effect of BNT162b2 on the human liver cell line Huh7 in vitro. www.mdpi.com |
'Lei de Não Discriminação de Informação Genética de 2008''.https://www.govinfo.gov/content/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf
PUBLIC LAW 110–233—MAY 21, 2008 122 STAT. 885 of paragraph (2) if such request, requirement, or purchase is not in violation of paragraph (1). ‘‘(e) APPLICATION TO ALL PLANS.—The provisions of subsections PPLICATION TO ALL PLANS.—The provisions of subsections F.— -.— www.govinfo.gov |
Comments
Post a Comment